DESENSITIZATION OF INOTROPIC RECEPTORS
======================================

Desensitization is a loss of receptor responsiveness which develops with continuous presence of agonist. Desensitization is a general phenomenon which can be observed in most membrane receptor types, either metabotropic or ionotropic. Unlike metabotropic receptors which desensitize mainly via receptor internalization, thereby temporarily subtracting responsive elements to the extracellular stimulus ([@B18], [@B18]), ionotropic receptor desensitization involves structural and functional changes in membrane residing receptors. The fundamental properties of acetylcholine (ACh) ionotropic receptor desensitization were originally described by [@B43] working on the frog neuromuscular junction (for review see [@B29]) and can still be used to supply important principles to understand desensitization of many ionotropic receptors including those activated by extracellular ATP.

Ionotropic ATP receptors comprise P2X1 -- P2X7 subtypes widely expressed in various tissues ([@B6]). The rate of desensitization and recovery processes vary widely within the family of P2X receptors ([@B60]). Thus, desensitization is developing very fast up to complete, yet reversible, loss of response in homotrimeric receptors composed of P2X1 and P2X3 subunits ([@B60]; [@B9]). In contrast, the other P2X subtypes are less prone to desensitization. One goal of the present review is to discuss how the strong desensitization process of P2X3 receptors can coexist with the function of P2X3 receptor activation in pain signaling and whether facilitating desensitization might actually be exploited for analgesic purposes. We aim at resolving this conundrum by taking into account the receptor kinetic properties and dynamics.

P2X3 RECEPTORS UNIQUE PROPERTIES
================================

P2X3 receptors are similar in some desensitization properties (fast onset and slow recovery) to the P2X1 subtype. However, their distinctive characteristics are listed below.

1.  Fast desensitization onset (ms range; similar time-course for P2X1 subtype)

2.  Very slow (min range) recovery from desensitization (shared with P2X1 subtype)

3.  High affinity desensitization (HAD) by very low agonist concentrations without generating a macroscopic current

4.  Heteromerization of P2X3 with P2X2 subunits to generate sustained non-desensitizing responses

5.  Remarkable resistance of desensitization onset to changes in temperature and divalent cation concentration

6.  Strong acceleration of recovery (resensitization) by increases in extracellular Ca^2+^ levels and inhibition by extracellular Mg^2+^

7.  Speed of recovery highly dependent on temperature (higher temperature, faster recovery)

8.  Recovery sensitive to signal transduction mechanisms and controlled by the specific modulators

These properties are described in more detail in the following sections of this review.

DESENSITIZATION ONSET OF P2X3 RECEPTORS
=======================================

P2X3 receptors can be activated by different agonists such as ATP, α,β-meATP, ATP-γ-S, β,γ-meATP, CTP, 2MeS-ATP and Bz-ATP which can all operate as full agonists ([@B74], [@B75]; [@B65]; [@B64], for reviews see [@B60]; [@B9]; [@B16]). Despite their different structures, all these compounds applied in high concentration can generate full size responses that, when recorded as membrane currents in voltage clamp conditions, show very similar fast decay ([@B75]).

The scheme of **Figure [1](#F1){ref-type="fig"}** shows that the agonist-bound open receptor can effect a dynamic transition to the closed, desensitized state persisting even when the agonist has come off the receptor. Thus, on P2X3 receptors, as expected from the classical model of desensitization by [@B43], the desensitization onset is accelerated by increasing the agonist dose ([@B75]) because the rate of this transition is strongly dependent on the agonist concentration and it, therefore, ensures that a large fraction of the available receptor population dwells in this functionally inactive state. Nevertheless, unlike the phenomenon observed with nicotinic receptors, the onset of P2X3 receptors desensitization is remarkably insensitive to temperature changes ([@B47]). There are only a few experimental manipulations which can specifically interfere with P2X3 receptor desensitization onset. One drug is the anti-inflammatory analgesic naproxen, which is widely used as an anti-migraine agent and which can speed up the desensitization onset of recombinant P2X3 receptors expressed in HEK cells ([@B34], see **Figure [1](#F1){ref-type="fig"}**). Conversely, acid pH slows down the development of desensitization, although this effect might be indirectly due to reduction of P2X3 receptor potency ([@B24]).

![**A simplified kinetic scheme for P2X3 receptor operation indicating resting, open and desensitized receptor states.** Note multiple factors accelerating (+, red arrow) or retarding (-, black arrow) recovery from desensitization, while naproxen promotes desensitization onset. Factors accelerating recovery are expected to facilitate ATP signaling via P2X3 receptor activity, whereas factors retarding recovery (or promoting desensitization onset) could provide the anti-nociceptive effect.](fncel-07-00245-g001){#F1}

SLOW RECOVERY FROM DESENSITIZATION
==================================

Restoration of the response after removal of agonist, indicating P2X3 receptor recovery from ATP-induced desensitization, is very slow and can take up to 20 min at room temperature ([@B10]). This outstanding property makes P2X3 (and P2X1) receptors very different from other ligand-gated receptors ([@B10]). Even though the recovery occurs very slowly, it proceeds to full return of P2X3 receptor response: this reversibility is a useful criterion to distinguish desensitization from the irreversible rundown which is a common feature of many ionotropic receptors including the P2X1 subtype ([@B53]).

We have previously shown that recovery of P2X3 receptors from desensitization is an agonist-specific process ([@B74]). It can be very fast for agonists like β,γ-meATP, but unusually slow for 2MeS-ATP ([@B75]). Furthermore, recovery displays distinctive properties from desensitization onset because, in addition to its time-course, it is modulated by factors such as temperature ([@B47]), cibacron blue ([@B1]), extracellular Ca^2+^ ([@B10]) and others listed in **Figure [1](#F1){ref-type="fig"}**. The independent modulation of desensitization onset and recovery suggests that they are likely to have different determinants (see details in the "Structural Determinants of Desensitization").

HIGH AFFINITY DESENSITIZATION
=============================

Apart from the "classical" desensitization arising from the open receptor state, there is an additional process of slow onset desensitization called "HAD" -- that is, a low nanomolar concentration of the agonist inhibits P2X3 receptor responses without evoking a macroscopic current ([@B57]; [@B74], [@B75]; [@B65]). We have shown that this phenomenon is also agonist-specific, being particularly strong for the natural agonist ATP ([@B74], [@B75]). Thus, ATP is about a 10-fold more potent inducer of HAD than α,β-meATP (IC~50~ 2 and 20 nM, respectively), even though both agonists have almost the same EC~50~ values ([@B74]).

Given that the ambient level of extracellular ATP in various tissues is in the nanomolar range ([@B49]; [@B51]), one might suggest that a fraction of P2X3 receptors is continuously inactivated *in vivo*. Such inactivation could largely reduce the ability of P2X3 receptor expressing neurons to detect and generate nociceptive signal in response to acute ATP release. Furthermore, diadenosine polyphosphates, that are endogenously produced by bridging two adenosine moieties with a chain of two or more phosphates, can act as powerful HAD inducers ([@B57]). This observation widens the range of substances that can modulate desensitization of P2X3 receptors and emphasizes the functional role of HAD as discussed in detail in the present review.

P2X3 ACTIVITY IS FACILITATED BY EXTRACELLULAR CALCIUM AND INHIBITED BY MAGNESIUM
--------------------------------------------------------------------------------

One outstanding feature of the P2X3 receptor is its unusual sensitivity to extracellular Ca^2+^ which is specifically targeting receptor desensitization. The exciting finding of the facilitatory action of extracellular Ca^2+^ on P2X3 receptor was first described by McClesky's group ([@B10]). Interestingly, Ca^2+^ selectively and positively controls the recovery stage of receptor desensitization without changes in desensitization onset ([@B30]). The most intriguing finding is that there is a sort of "memory" of the receptor system which remains in the facilitated state for several mins after the initial *transient* contact with the divalent cation ([@B10]). Such resensitization by Ca^2+^ on P2X3 receptor is functionally opposite to the well documented inhibitory action of Ca^2+^ on other P2X receptor subtypes ([@B79]; [@B14]). In fact, in the case of P2X2 receptors, extracellular Ca^2+^ rather promotes desensitization ([@B14]).

We have previously observed that, on native P2X3 receptors, extracellular Mg^2+^ can produce an opposite effect to Ca^2+^ ([@B30]). Thus, Mg^2+^ delays receptor recovery from desensitization, while the onset of desensitization remains unchanged. Ca^2+^-free solution has the similar inhibitory action on receptor resensitization. As the modulatory effects were observed with physiological concentrations of Ca^2+^, these finding outline a potential role of this mechanism even *in vivo*.

Our recent study has demonstrated that a single aminoacid (S275) within the left flipper region of the P2X3 receptor ectodomain is a likely determinant for the facilitatory action of extracellular Ca^2+^ ([@B64]). Thus, in the A275 mutant, extracellular Ca^2+^ induces an inhibitory effect on P2X3 receptor mediated responses instead of the facilitation normally seen with wildtype (WT) receptors.

UNUSUALLY HIGH TEMPERATURE SENSITIVITY
======================================

Another unexpected desensitization property of P2X3 receptors was described in detail by Krishtal's group. They showed that, while the desensitization onset is almost temperature insensitive, the recovery process is very temperature sensitive with a Q~10~ coefficient of about 10 ([@B47]). The temperature sensitivity of HAD is also high but clearly smaller than the one of the recovery process ([@B47]). These findings suggest that, unlike most *in vitro* experiments performed at room temperature, the recovery process at normal body temperature is much faster and that, in physiological conditions, the probability of repeated receptor activation is strongly enhanced.

Interestingly, the recycling of P2X3 receptors in the peri-membrane region measured by the TIRF/FRAP technique also shows very high sensitivity to temperature ([@B66]).

KINETIC MODELING OF P2X3 RECEPTOR DESENSITIZATION
=================================================

A formal description of P2X3 receptor behavior using kinetic modeling allows the exploration of silent receptor conformations, prediction of new receptor desensitization properties, and provides a mechanistic explanation for experimentally observed phenomena. Modeling of P2X3 receptor kinetics clearly indicates that a cyclic scheme of receptor reversible transitions modified from the original proposal by [@B43] is the most suitable to account for the experimental data which cannot be adequately explained with linear or bifurcation models ([@B75]). This model integrates all the main steps of P2X3 function such as binding, gating and desensitization, which are presented in an over-simplified form in **Figure [1](#F1){ref-type="fig"}**.

In the complete receptor model with full activation caused by three agonist molecules bound to it, the receptor transition into the desensitized state occurs mainly from the open state. Furthermore, this model can simulate HAD, implying the existence of a single molecule bound desensitized state with high agonist affinity ([@B75]). As a result, the model fully reproduces all the main properties of the P2X3 receptor, including fast desensitization, slow recovery and HAD.

The rate limiting role of agonist dissociation from the desensitized state for resensitization obtained with this theoretical approach accords with agonist unbinding from P2X3 receptors measured using radiolabeled ATP ([@B65]). Most importantly, the kinetic model predicts that desensitization, being the next step after binding of ATP and channel opening, should depend not only on "intrinsic" desensitizing properties of the P2X3 receptor, but also on agonist binding and channel gating. This view is essential when trying to find out and analyze the numerous data on structural determinants of desensitization.

To explain P2X3 receptor operation and in particular HAD, [@B41] have subsequently proposed an allosteric model that retains the cyclic scheme of [@B75], but it adds to it an additional transition, namely a receptor open state occurring when two rather than three ATP molecules are bound. Thus, [@B41] argue that their revised model is the simplest way to explain increased affinity of non-occupied binding sites when receptors are partially occupied. Future biophysical studies using microscopic recording of single channel currents may be necessary to clarify this proposal.

STRUCTURAL DETERMINANTS OF DESENSITIZATION
==========================================

At membrane level functional homomeric P2X3 receptors are assembled as trimers, whereby each subunit is composed of a large extracellular loop containing the ATP binding domain, two transmembrane domains and intracellular N- and C- termini (for reviews see [@B45]; [@B46]; [@B42], [@B16]). This complex structure has been extensively probed to find out the molecular determinants of desensitization.

One pioneer study showed that, using recombinant receptors expressed in Xenopus oocytes, chimeric P2X2 receptors containing P2X1 or P2X3 domains acquire strong desensitization, while chimeric P2X1 or P2X3 receptors with P2X2 domains show very weak desensitization ([@B80]). The domains necessary to alter the desensitization phenotype include the most hydrophobic segments of the molecules, which are thought to be membrane-spanning segments ([@B80]). These findings led [@B80] to propose that desensitization requires the interaction of these receptor long segments (comprising 34 aminoacids).

Many subsequent studies were focused on finding key residues determining the desensitization process of P2X receptors. Thus, it has been shown that certain C-terminus residues are important to express the slow desensitization of P2X2 receptors ([@B48]; [@B71]). Likewise, the N-terminus half of the P2X3 receptor ectodomain plays a role in the slow recovery from desensitization ([@B83]).

Our previous study has identified several residues in the ectodomain which determine the desensitization properties including Glu111, Asp220, and Asp266 ([@B17]). By site-directed mutagenesis to alanine, it was possible to observe a pleiotropy of receptor responses like fast onset combined with either faster or slower recovery (Glu111Ala and Asp220Ala, respectively), or very slow onset (resembling the non-desensitizing P2X2 receptor) combined with fast recovery (Asp266Ala). These various combinations of kinetic properties provide additional evidence for the existence of independent determinants of desensitization onset and recovery.

Our *in silico*exploration of the P2X3 receptor molecular model predicted that S275 within the ectodomain region termed *left flipper* as a contributor to ATP binding and suggested that its manipulation would result in changes in the desensitization properties ([@B64]). Indeed, substituting S275 with alanine produces a mutant with slow desensitization onset, fast resensitization and lack of HAD ([@B64]). In this experiment, HAD remained minimal even with higher agonist concentrations (to compensate for reduced potency), suggesting that this residue is indeed important to express the inhibitory action of low nanomolar concentrations of ATP. Substituting S275 with more hydrophobic aminoacids further slows down desensitization onset and accelerates recovery, indicating these two properties to be reciprocally interrelated ([@B64]).

Manipulations of the transmembrane P2X3 domains have indicated additional contributors to shape desensitization. Thus, substitution with alanine (or phenylalanine) of the highly conserved Y37 yields initial fast desensitization with a large residual current, remarkably resistant to further desensitization ([@B39]; see **Figure [2A](#F2){ref-type="fig"}**). Unlike the WT, this long lasting persistent current (highlighted by red arrow in **Figure [2B](#F2){ref-type="fig"}**) is systematically observed in the Y37A mutant in the presence of four different agonists (**Figure [2B](#F2){ref-type="fig"}**) applied at saturating concentrations that induce analogous amplitude of membrane current (**Figures [2C,D](#F2){ref-type="fig"}**). The latter indicated that this unusual plateau-like current is independent from the nature of the agonist. In sharp contrast, at the end of the agonist application, a highly variable (agonist-specific) rate of deactivation is observed (**Figure [2B](#F2){ref-type="fig"}**). This variable deactivation is related to the EC~50~ values for each agonist (**Figure [2E](#F2){ref-type="fig"}**). Furthermore, the rate of deactivation correlates also with the rate of agonist dissociation from the desensitized receptor state (fast deactivation, fast dissociation, see [@B75]). Kinetic modeling may help to explain these unusual phenomena by assuming facilitated re-opening of the P2X3 channels from the desensitized to the conducting states ([@B39]).

![**The action of different agonists on the WT and Y37A receptor.** **(A)** Currents activated by 2 s application of β,γ-meATP, α,β-meATP, ATP, or 2MeS-ATP (all 100 μM) on WT receptors. **(B)** Currents activated by 2 min application of β,γ-meATP, α,β-meATP, ATP, or 2MeS-ATP (in keeping with higher potency, all at 10 μM) on Y37A mutant receptors. Note similar peak amplitudes and plateau-like components (red arrows) but different current decays during the washout phase. **(C,D)** Histograms showing the mean amplitudes of peak currents induced by different agonists on WT **(C)** or Y37A receptor **(D)**. **(E)** Graph showing a correlation between differential agonist-specific current decays (measured after 30 s of washout) and corresponding EC~50~ values for each agonist. Datapoints from 3 to 12 cells. Reproduced with modifications from [@B39] with permissions from John Wiley and Sons.](fncel-07-00245-g002){#F2}

In conclusion, current evidence shows multiple determinants of desensitization throughout the whole receptor structure (ectodomain, transmembrane and intracellular termini).

Useful clues to the biophysical nature of desensitization may also come by comparing P2X3 receptors with sister receptors containing other P2X subunits. Thus, using voltage clamp fluorometry applied to the P2X1 subtype, which is also prone to fast desensitization, [@B54] have proposed that the cys-rich *head* domain of this receptor is involved in both channel activation and desensitization. In the P2X1 subtype, high sensitivity to low doses of ATP is also reported, although desensitization in this case develops after detectable membrane currents ([@B68]). Despite the fact that P2X7 receptors have low affinity for their natural ligand ATP (active at mM concentrations), ongoing desensitization has also been proposed to exist in this subtype, yet masked by the overlapping process of ion pore widening ([@B44]).

FUNCTIONAL ROLE OF DESENSITIZATION OF P2X3 RECEPTORS
====================================================

Nowadays there is strong evidence that P2X3 receptors participate in chronic pain, a most distressing clinical state often resistant to treatment ([@B5]; [@B61]). In fact, P2X3 channels are almost exclusively expressed by nociceptive neurons ([@B7]; [@B52]), and impaired pain-evoked responses (especially of inflammatory type) are observed in P2X3 knockout mice ([@B8]; [@B76]). These data accord with earlier reports that injection of α,β-meATP into the rat paw evokes strong nociceptive behavior which is paradoxically prevented by a previous application of the same agonist ([@B3]), pointing to a functional role of P2X3 receptor desensitization in shaping pain responses *in vivo*. However, in view of the fast desensitization of P2X3 receptors and the high likelihood of their HAD because of ambient ATP (and its metabolites), one may wonder how to reconcile such characteristics with a functional role of these receptors in sustained pain signaling ([@B61]).

One possible explanation is that, in healthy subjects, the main role of HAD in ATP-gated P2X3 receptors is to prevent inappropriate excitation of nociceptive pathways (and associated pain sensitivity) when there is a high probability of ATP release from surrounding tissues. In other words, HAD might be viewed as an intrinsic mechanism of "anti-nociception" in normal states, working in cooperation with fast desensitization to restrict ATP-mediated signaling. This protective process might be important in conditions like physical exercise when there is a continuous release of ATP in muscles to the level comparable with EC~50~ of P2X3 receptors ([@B35]; [@B58]).

Assuming a constitutive inhibition of P2X3 receptor activity by ambient purines, only strong, burst-like ATP release can perhaps represent a stimulus large enough to overcome any intrinsic anti-nociceptive effect ([@B28]). In contrast, in chronic pain in man, particularly of inflammatory origin, P2X3 receptors might play a direct pro-nociceptive role ([@B5]) because the desensitization properties of P2X3 receptors could be modified by several cellular mechanisms that collectively or individually promote nociceptive sensitization (**Figure [1](#F1){ref-type="fig"}**):

1.  removal of ambient ATP via extracellular NTDases;

2.  decreased HAD;

3.  accelerated recovery from desensitization;

4.  heteromerization with non-desensitizing P2X2 receptors.

Although the *first mechanism* of sensitization has not been studied in relation to pain, its feasibility is indirectly supported by experiments on taste buds ([@B78]). In fact, recent studies have shown expression of P2X3 receptors (along with P2X2 ones) in nerves supplying the taste buds ([@B19]). Using the NTDase-2 knockout mouse, it has been observed that excessive levels of extracellular ATP generated in the taste bud could inactivate nerve terminal P2X receptors and block the taste response by promoting desensitization via a phenomenon resembling HAD ([@B78]). Thus, the extent of breakdown and clearance of extracellular ATP may be important to regulate nociceptive purinergic signaling.

As for the *second mechanism*of sensitization, evidence clearly shows that resensitization of P2X3 receptors *in vivo*is much faster than *in vitro* ([@B47]), and may be expected to occur even faster if local inflammatory reaction raises tissue temperature. Furthermore, inflammatory cells like macrophages releasing TNFα can further upregulate P2X3 receptor activity ([@B23], [@B22]). It is also noteworthy that human P2X3 receptors recover about twice faster than analogous rodent receptors ([@B65]). Finally, the P2X3 receptor recovery may be accelerated, via release of neuropeptides and neurotrophins ([@B15]; [@B13]) and by extracellular acidification ([@B24]) which occurs in inflammation and cancer ([@B77]). Thus, the migraine mediator CGRP not only largely increases the amplitude of P2X3 currents generated in nociceptive trigeminal neurons, but it also significantly speeds up recovery from desensitization via an intracellular kinase-dependent process of P2X3 receptor phosphorylation ([@B15]; [@B28]).

The possibility of the *third mechanism* of sensitization via reduced HAD is supported by decreased inhibitory action of nanomolar ATP at higher temperature ([@B47]).

Finally, enhanced expression of heteromeric P2X2/3 receptors producing typically non-desensitizing plateau currents might be the *fourth mechanism* of sensitization contributing to nociceptive signaling ([@B61]). However, recent study revealed the prevailing expression of P2X3 subunits in dorsal root ganglion neurons in primates, including human sensory neurons ([@B69]). Thus, the contribution of P2X2/3 receptors to chronic pain is probably more important at the level of nociceptive pathways within the spinal dorsal horn as indicated by the inhibition of nociceptive neuron firing by A-317491, a potent P2X2/3 antagonist ([@B82]).

A proposal for the physiological role of desensitization should also include mechanisms which augment this inhibitory process. Indeed, recovery from desensitization can be delayed via GPCR signaling (**Figure [1](#F1){ref-type="fig"}**) involving P2Y receptors ([@B25]), GABA~B~ receptors ([@B73]) and unidentified membrane receptors activated by extracellular cAMP ([@B55]). These mechanisms may be additional to the intrinsic inhibition of P2X3 receptor activity via C-terminal Src inhibitory kinase (Csk)-mediated tyrosine phosphorylation of the receptor ([@B12]). Future studies should address whether in chronic pain models there is a disruption in the intricate molecular mechanisms regulating P2X3 expression and function.

ANALGESIC DRUGS PROMOTING DESENSITIZATION OF P2X3 RECEPTORS
===========================================================

INFLAMMATORY AND NEUROPATHIC PAIN
---------------------------------

The anti-nociceptive action of the selective P2X3 antagonist A-317491 in inflammatory and neuropathic pain was first reported in a study aimed at counteracting chronic pain in animal models ([@B38]). The traditional pharmacological approach to anti-nociception is usually based on the development of receptor antagonists with good bioavailability, high specificity, and minimal side-effects. One such example is a novel selective P2X3/P2X2/3 receptor antagonist AF-353 which is orally bioavailable ([@B26]). Other potential analgesic agents with different structure based on P2X3 receptor antagonism are reviewed by [@B32] and by A. P. Ford in this series. Some of these compounds are already investigated in clinical trials, although none of them has yet received statutory approval by regulatory agencies for human use ([@B20]). A new line in drug development for the prevention of P2X3 mediated pain should target facilitation of desensitization. In fact, [@B3] have previously shown that an analgesic effect could be induced by injection of the full P2X3 agonist, α,β-meATP after an initial pro-nociceptive effect. More promising clues for pain suppression treatment may, however, come from the use of promoters of desensitization which show little or no agonist activity. Thus, purotoxin-1, a peptide recently isolated from the Asian wolf spider Geolycosa, powerfully inhibits P2X3 receptors by strongly promoting their desensitized state and provides effective anti-nociception in various pain models *in vivo* ([@B31]) while the antagonist P1, P5-di\[inosine-5^′^\] pentaphosphate binds to the desensitized state of the P2X3 receptor in DRG neurons ([@B21]).

MIGRAINE AND TRIGEMINAL PAIN
----------------------------

Mg^2+^ can hardly be considered as a selective anti-migraine agent, and is typically known to be the endogenous blocker of NMDA channels ([@B62]). There are, however, repeated suggestions to include this agent in the complex therapy of trigeminal migraine pain (this subject has been extensively discussed by [@B63]; and [@B56]). As Mg^2+^ inhibits desensitizing ATP-evoked currents in rat cultured sensory neurons ([@B30]), this effect might be considered to contribute to its analgesic action *in vivo* ([@B11]). Given that Mg^2+^ specifically interferes with desensitized receptor states, one could expect the use-dependent anti-nociceptive action of this divalent cation in pain mediated by high concentrations of ATP acting on the P2X3 receptor. Of course, modulation by Mg^2+^ of P2X3 receptor activity may be complementary to the divalent cation role in NMDA receptor function that is thought to be dysregulated in trigeminal ganglia and underlying pain sensitization ([@B50]).

The high expression of P2X3 receptors by the vast majority of trigeminal sensory neurons ([@B70]) provides the molecular substrate for P2X3 mediated trigeminal pain including migraine ([@B28]). In experimental model of trigeminal pain *in vitro*, expression of P2X3 membrane receptors by trigeminal neurons is amplified by the migraine mediator CGRP that operates via intracellular kinases and enhanced P2X3 receptor trafficking from intracellular compartments ([@B15]). Likewise, in transgenic mice expressing human mutated P/Q calcium channels as observed in Familial Hemiplegic Migraine type 1, the activity of P2X3 channels is constitutively enhanced ([@B59]) probably because of the higher background release of CGRP as shown by the phenotype reversal evoked by a CGRP receptor antagonist ([@B36]). To further support the role of PX3 receptors in migraine pain, there are data obtained with well-established anti-migraine drugs. Thus, naproxen, a popular anti-headache analgesic, directly inhibits P2X3 receptors by facilitating receptor desensitization (**Figure [1](#F1){ref-type="fig"}**), an inhibitory effect that is potentiated in the presence of the algogen nerve growth factor ([@B34]), the level of which is elevated in patients with chronic migraine ([@B37]).

CANCER PAIN
-----------

Accumulating evidence suggests the involvement of P2X3 receptors in bone tissue cancer pain. The bone has a very specific environment including diverse cell populations and a specialized hormonal control by parathyroid hormone and parathyroid hormone-related protein which regulate Ca^2+^ release from osteoclasts ([@B72]). Thus, in bone cancer there is a massive release of Ca^2+^ leading eventually to hypercalcaemia which as mentioned above is a potent and unique mechanism to facilitate, via resensitization, the function of P2X3 receptors. In some pathological conditions, for instance, during parathyroid hormone-related protein-mediated hypercalcemic crisis, the serum Ca^2+^ can raise from normal level of \~1.5 mM up to 4.8 mM ([@B67]). There can be also malignancy-associated hypercalcemia, often associated with headache when the level of Ca^2+^ released from osteoclasts is rising locally within the bone ([@B2]). When the intense ATP release coincides with local enhancement of extracellular Ca^2+^ this could result in a strong nociceptive firing through increased activity of P2X3 receptors. The antagonism of Ca^2+^ effect on P2X3 receptor by Mg^2+^ ([@B30]) can provide a rationale for the high analgesic efficiency of the latter in cancer pain ([@B11]). Thus, the selective P2X3, P2X2/3 receptor antagonist A-317491 transiently attenuates cancer-induced bone pain in mice, but has no effect at the late stage of bone cancer ([@B33]). Bone cancer pain in rats is reduced by the blockade of P2X3 and P2X2/3 receptors with AF-353 ([@B40]). Furthermore, there is an increased expression of P2X3 receptors in CGRP immunoreactive nerves during tumor growth suggesting their role in cancer-related pain ([@B27]). Likewise, P2X3 receptors are functionally up-regulated in dorsal root ganglion neurons of a rat model of bone cancer ([@B81]).

CONCLUSION
==========

Desensitization of nicotinic ACh receptors is now considered an important process for neuronal signaling in health and disease ([@B29]). In fact, there are ongoing efforts to develop drugs ("silent desensitizers"; [@B4]) to modulate cholinergic function via receptor desensitization. The path is, therefore, open to look for chemical agents to desensitize P2X3 receptors selectively and to discover their impact on physiological or pathological conditions.
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